Arch Therapeutics Inc (ARTH)

Arch Therapeutics Stock Analysis & Ratings

ARTH Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.04 - $0.14
Previous Close$0.05
Average Volume (3M)207.26K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-2.1
Next EarningsMay 14, 2019
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart ScoreN/A



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Arch Therapeutics’s price range in the past 12 months?
Arch Therapeutics lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
    What is Arch Therapeutics’s market cap?
    Currently, no data Available
    What is Arch Therapeutics’s price target?
    Currently, no data Available
    What do analysts say about Arch Therapeutics?
    Not enough analysts have published a price target to provide an average price target.
    When is Arch Therapeutics’s upcoming earnings report date?
    Arch Therapeutics’s upcoming earnings report date is May 14, 2019 which is 1147 days ago.
      How were Arch Therapeutics’s earnings last quarter?
      Arch Therapeutics released its earnings results on Feb 01, 2019. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.013 by -$0.007.
        Is Arch Therapeutics overvalued?
        According to Wall Street analysts Arch Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Arch Therapeutics pay dividends?
          Arch Therapeutics does not currently pay dividends.
          What is Arch Therapeutics’s EPS estimate?
          Arch Therapeutics’s EPS estimate is -$0.01.
            How many shares outstanding does Arch Therapeutics have?
            Arch Therapeutics has 237,069,760 shares outstanding.
              What happened to Arch Therapeutics’s price movement after its last earnings report?
              Arch Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.013. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Arch Therapeutics?
                Currently, no hedge funds are holding shares in ARTH


                Arch Therapeutics Stock Analysis

                Smart Score
                Not Ranked
                Price Target
                No data currently available
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Arch Therapeutics Inc

                Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.

                Similar Stocks
                Price & Change
                Apyx Medical
                Advance Auto Parts
                O'Reilly Auto
                Ocular Therapeutix

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis